^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Ganglioglioma
    Drug Class:BRAF inhibitor +
    MEK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Neurology
    Title:

    Sustained Tumor Control With MAPK Inhibition in BRAF V600-Mutant Adult Glial and Glioneuronal Tumors

    Published date:
    08/17/2021
    Excerpt:
    Twenty-eight adults with recurrent or disseminated BRAF V600-mutant gangliogliomas (n = 9), pleomorphic xanthoastrocytomas (n = 9), and diffuse gliomas (n = 10) were included in the study….Our study highlights the long-term clinical benefits of RAFi/MEKi in adult patients with BRAF V600-mutant GGNTs...
    DOI:
    10.1212/WNL.0000000000012330